ClinicalTrials.Veeva

Menu

Regional Hypothermia in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke (RE-HIBER)

C

Capital Medical University

Status

Unknown

Conditions

Stroke
Hypothermia
Neuroprotection

Treatments

Other: Regional Hypothermia

Study type

Interventional

Funder types

Other

Identifiers

NCT04554797
RE-HIBER

Details and patient eligibility

About

The investigators have previous shown that regional hypothermia by the intra-arterial infusion of cold saline combined with mechanical thrombectomy in acute ischemic stroke is feasible and safe. The safety of selective brain cooling in patients undergoing mechanical thrombectomy, however, is not established in a randomized trial. The investigators therefore conducted this RCT study to further explore the safety of regional hypothermia in patients with acute ischemic stroke who underwent mechanical thrombectomy.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 and ≤80
  • Clinical signs consistent with the diagnosis of an acute ischemic stroke
  • Baseline NIHSS score obtained prior to randomization ≥8
  • Intracranial arterial occlusion of the distal intracranial carotid artery or
  • Middle (M1/M2), demonstrated with CTA, MRA, DSA
  • The possibility to start treatment (artery puncture) within 6 hours from onset
  • Regional hypothermia is expected to start within 15 minutes after recanalization
  • Informed consent given

Exclusion criteria

  • mTICI<2b after endovascular treatment
  • No significant pre-stroke disability (mRS ≤1)
  • Previous NYHA grade > 1
  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0
  • Baseline platelet count < 50000/µL
  • Baseline blood glucose of < 50mg/dL or >400mg/dl
  • Severe, sustained hypertension (SBP > 220 mm Hg or DBP > 110 mm Hg). NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using local treatment guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.
  • Seizures at stroke onset which would preclude obtaining a baseline NIHSS
  • Subjects who have received iv t-PA treatment beyond 4,5 hours from the beginning of the symptoms
  • Renal insufficiency with creatinine ≥ 3 mg/dl
  • Woman of childbearing potential who is known to be pregnant or lactating
  • Subject participating in a study involving an investigational drug or device that would impact this study
  • Cerebral vasculitis
  • Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations
  • Unlikely to be available for 3 months follow-up (e.g. no fixed home address, visitor from overseas).
  • CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed)
  • ASPECT<6
  • Subjects with occlusions in multiple vascular territories (anterior circulation and posterior circulation)
  • Evidence of intracranial tumor (except small meningioma)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

60 participants in 2 patient groups

Regional Hypothermia group
Experimental group
Treatment:
Other: Regional Hypothermia
Control group
No Intervention group

Trial contacts and locations

2

Loading...

Central trial contact

Chuanjie Wu, MD; Xunming Ji, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems